Recently, the World Health Organization (WHO) released its updated Bacterial Priority Pathogens List (BPPL) 2024.
About Bacterial Pathogens Priority List:
It is an important tool in the global fight against antimicrobial resistance.
Background
In 2017, WHO developed the first BPPL to guide investment into the R&D of new antibacterials and it listed 13 bacterial pathogens (phenotypes).
It was developed with the multi-criteria decision analysis (MCDA) method (15).
MCDA is a decision-making scientific method that mounts and evaluates alternatives based on multiple criteria, facilitating systematic and transparent decision-making in complex options.
The 2024 WHO BPPL covers 24 pathogens, spanning 15 families of antibiotic-resistant bacterial pathogens.
The 2024 list categorizes these pathogens into critical, high, and medium priority groups to inform research and development (R&D) and public health interventions.
Significance
The WHO BPPL acts as a guide for prioritizing R&D and investments in AMR, emphasizing the need for regionally tailored strategies to effectively combat resistance.
It targets developers of antibacterial medicines, academic and public research institutions, research funders, and public–private partnerships investing in AMR R&D, as well as policy-makers responsible for developing and implementing AMR policies and programs.
What is Antimicrobial Resistance (AMR)?
It occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines,making people sicker and increasing the risk of disease spread,illness and deaths.
It is driven in large part by the misuse and overuse of antimicrobials.
Comments